Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q3 2023

Q3 2023 biggest moves
  • AMEDAMED

    AMEDISYS

    Sold out

    was 3.5% of portfolio

  • BIOBIO

    Bio-Rad Laboratories

    New

    1.4% of portfolio

  • CNCCNC

    Centene

    Added 48%

    now 3.0% of portfolio

  • IARTIART

    Integra LifeSciences

    New

    0.9% of portfolio

73 changes in all

Top Holdings88 positions

Checking export access…
Activity:
NUVL
NUVLDelisted

NUVALENT INC

20M$919M20.2%——
9 qtrssince 2021-Q3
Unchanged
0
??
GLAUKOS CORPDelisted
Bond
271.5M$426.5M9.4%——
10 qtrssince 2021-Q2
Unchanged
0
VTRS

Viatris Inc.

19.9M$195.9M4.3%$11.25-22.73%
12 qtrssince 2020-Q4
Increased
63
??
217.8M$163.8M3.6%——
1 qtr
New
84
144.5M$141.5M3.1%——
11 qtrssince 2021-Q1
Unchanged
0
CNC

Centene Corporation

2M$137.1M3.0%$66.13+4.15%
16 qtrssince 2019-Q4
Increased
76
NBIX

Neurocrine Biosciences, Inc.

1.2M$136.1M3.0%$95.92+17.28%
11 qtrssince 2021-Q1
Unchanged
0
??
NATERA INCDelisted
Bond
101M$133.5M2.9%——
10 qtrssince 2021-Q2
Unchanged
0
AHCO

AdaptHealth Corp.

13.6M$123.8M2.7%$18.05-49.57%
16 qtrssince 2019-Q4
Increased
62
146M$114.3M2.5%——
4 qtrssince 2022-Q4
Unchanged
0
??
ACCOLADE INCDelisted
Bond
132.6M$107.9M2.4%——
6 qtrssince 2022-Q2
Increased
56
??
INSMED INCDelisted
Bond
108.9M$107.6M2.4%——
15 qtrssince 2020-Q1
Increased
54
98.4M$105.1M2.3%——
5 qtrssince 2022-Q3
Unchanged
0
ACH

Accendra Health, Inc.

6.4M$104M2.3%$16.50-2.05%
4 qtrssince 2022-Q4
Increased
67
CPRX
CPRXDelisted

CATALYST PHARMACEUTICALS INC

8.2M$95.8M2.1%——
5 qtrssince 2022-Q3
Unchanged
0
MRUS
MRUSDelisted

MERUS N V

3.9M$91.4M2.0%——
8 qtrssince 2021-Q4
Increased
64
DCPH
DCPHDelisted

DECIPHERA PHARMACEUTICALS IN

6.9M$87.7M1.9%——
16 qtrssince 2019-Q4
Increased
48
LRMR

Larimar Therapeutics, Inc.

16.9M$66.9M1.5%$6.40-38.27%
14 qtrssince 2020-Q2
Unchanged
0
BIO

Bio-Rad Laboratories, Inc.

173,947$62.4M1.4%$358.450.00%
1 qtr
New
67
IDYA

IDEAYA Biosciences, Inc.

2.3M$61.2M1.3%$16.91+59.59%
5 qtrssince 2022-Q3
Unchanged
0
$4.5B
AUM
88
Positions
Q3 2023
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2022-Q2$4,848,381,0008.39346149048%
2022-Q3$5,023,740,0003.61685684355%
2022-Q4$4,831,008,337-3.83641794758%
2023-Q1$4,485,670,170-7.14836619832%
2023-Q2$4,684,196,2414.42578396262%
2023-Q3$4,538,793,245-3.10411836992%
Activity profile
$ moved · Q3'23
New32%Increased14%Decreased5%Exited50%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.0 years
<1Q19%1-4Q7%1-2Y5%2Y+69%

Deerfield Management Company, L.P. manages $4.5B across 88 positions as of Q3 2023. Top holdings: NUVL (20.2%), GLAUKOS CORP (9.4%), VTRS (4.3%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$5B
NUVL20.25%
GLAUKOS CORP9.40%
VTRS4.32%
Invitae Corp3.61%
TABULA RASA 3.12%
CNC3.02%
NBIX3.00%
NATERA INC2.94%
AHCO2.73%
BROOKDALE SR2.52%
Other2.38%

Portfolio allocation by GICS sector

Sectors2
Healthcare90.74%
Unknown9.26%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used